

AIDS Drug Assistance Program
ADAP Advisory Work Group
February 9, 2007 Conference Call Minutes

Present were: Jerry Jean Stambaugh, R.Ph., Mike Wallace, R.N., Mike Ehren, R.Ph., Javier Romero, Paul Arons, M.D., Susan Kramer, R.N., Joe May, Lorraine Wells, and Cyndena Hall

Three members were unable to access the call due to technical difficulties; however, their comments prior to the call were incorporated.

The meeting convened on February 9, 2007 in Tallahassee, FL. There were opening comments by Lorraine Wells, introductions were made, and the order of business ensued.

Lorraine Wells began the discussion by summarizing the purpose of the call. She further explained that the contracted price for the testosterone gel Testim® with Auxilium Pharmaceuticals, Inc., was to extend through December 31, 2007, but was cancelled by the company. Auxilium has chosen to exercise their 60 days notice clause and cancel the current agreement. In addition, Auxilium has executed a new agreement for the brand name drug Testim® for double the amount of the original contracted price.

After further consultation with the AIDS Drug Assistance Program Statewide Advisory Workgroup, as well as input from the Bureau Medical Consultant Team, a motion by Dr. Paul Arons was raised to remove Testim® from the formulary. The motion was seconded and then passed. Although Testim®, a form of testosterone, has been removed from the formulary, there are other versions of testosterone that will remain on the Florida ADAP formulary.